Burden of HIV and hepatitis C co-infection: The changing epidemiology of hepatitis C in HIV-infected patients in France

Liver International

Volumn 35, Issue 1, 2015, Pages 65-70

  Cacoub, Patrice ^a,b,c   Dabis, François ^d   Costagliola, Dominique ^a,e   Almeida, Kayigan ^f   Lert, France ^f   Piroth, Lionel ^g   Semaille, Caroline ^h  

^a SORBONNE UNIVERSITÉ   (France)

^b Sorbonne Université   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

^e INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g UNIV BOURGOGNE FRANCHE COMTÉ   (France)

^h Unité d'hémovigilance Agence nationale de sécurité du médicament et des produits de santé   (France)

Author keywords

Epidemiology; HCV; HIV

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC ACTIVE HEPATITIS; EPIDEMIOLOGICAL DATA; FEMALE; FRANCE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PREVALENCE; VIRUS LOAD; COINFECTION; DRUG USE; HISTORY; HIV INFECTIONS; MALE HOMOSEXUALITY; STATISTICS AND NUMERICAL DATA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; DRUG USERS; FRANCE; HEPATITIS C; HISTORY, 21ST CENTURY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PREVALENCE;

EID: 84921030343     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12639     Document Type: Article

References (33)

1. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 221-217.
2. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
3. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1-4.
4. Rosenthal E, Poirée M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.
5. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death in HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
6. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus. The D:A:D study. Arch Intern Med 2006; 166: 1632-41.
7. Rosenthal E, Pialoux G, Bernard N, et al. Liver-related mortality in human immunodeficiency virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183-8.
8. Rosenthal E, Salmon-Céron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC joint study group network (Mortavic 2005 study in collaboration with the Mortalite' 2005 survey, ANRS EN19). HIV Med 2009; 10: 282-9.
9. Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV co-infected persons. N Engl J Med 2004; 351: 451-9.
10. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
11. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated-interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
12. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.
13. Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential weapon for the outbreak of blood borne viruses in the community. Ann Med Health Sci Res 2013; 3: 177-81.
14. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013; 26: 66-72.
15. Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 2009; 16: 113.
16. Cacoub P, Halfon P, Rosenthal E, et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in the real life: modifications in two large surveys between 2004 and 2006. J Hepatol 2008; 48: 35-42.
17. Cacoub P, Halfon P, Rosenthal E, et al. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between, 2004 and 2009. J Hepatol 2010; 53: 230-7.
18. 4). Int J Epidemiol 2014; doi: 10.1093/ije/dyu002
19. Roux P, Demoulin B, Sogni P, et al. La co-infection par le virus de l'hépatite C chez les personnes infectées par le VIH: données de l'enquête ANRS-VESPA2. BEH 2013; 26-27: 314-20.
20. Loko MA, Salmon D, Carrieri P, et al. ANRS CO 13 HEPAVIH study group. The French national prospective cohort of patients co-infected with HIV and HCV: early findings, 2006-2010. BMC Infect Dis 2010; 10: 303.
21. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The 'Mortalité 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-8.
22. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (ANRS EN20 Mortalité 2010 study)-trends since 2000. AIDS 2014; 28: 1181-91.
23. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
24. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
25. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of deaths in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195-207.
26. Van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2013; 144: 751-60.
27. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-93.
28. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV co-infection on the risk of cirrhosis and hepatocellular carcinoma un US veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.
29. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study. J Hepatol 2007; 47: 447-50.
30. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. J Hepatol 2009; 50: 736-45.
31. Merchante N, Merino E, López-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56: 143-50.
32. Cacoub P, Rosenthal E, Salmon D, et al. Liver related deaths in HIV-infected patients between 2000 and 2010. Results of the French national survey 'ANRS EN20 Mortalite 2010'. J Hepatol 2012; 56: 23.
33. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4: 437-44.